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1. Introduction {#ehf212567-sec-0005}
===============

Heart failure (HF) is a global health issue with a prevalence between 1% and 2% in Western countries,[1](#ehf212567-bib-0001){ref-type="ref"}, [2](#ehf212567-bib-0002){ref-type="ref"} an estimated 26 million affected worldwide,[3](#ehf212567-bib-0003){ref-type="ref"} and one of the leading sources of health care resource use and expenditure.[4](#ehf212567-bib-0004){ref-type="ref"} Although in Western countries there is currently a trend towards a reduction in the incidence of HF with reduced ejection fraction \[HFrEF; left ventricular ejection fraction (LVEF) ≤40%\],[5](#ehf212567-bib-0005){ref-type="ref"} it still represents almost one‐third of incident HF cases[6](#ehf212567-bib-0006){ref-type="ref"} and has a mortality rate of 8.8% at 1 year.[7](#ehf212567-bib-0007){ref-type="ref"}

Pharmacological management of HFrEF aims to regulate the physiological compensatory response to low cardiac output, which in the long‐term prompts maladaptive cardiac remodelling finally leading to chronic HF.[8](#ehf212567-bib-0008){ref-type="ref"} Blocking the adrenergic and the renin--angiotensin--aldosterone systems has been the classical target of HF drugs.[9](#ehf212567-bib-0009){ref-type="ref"}, [10](#ehf212567-bib-0010){ref-type="ref"}, [11](#ehf212567-bib-0011){ref-type="ref"} In addition, drugs that reduce heart rate through inhibition of sinoatrial cardiac myocites, such as ivabradine,[12](#ehf212567-bib-0012){ref-type="ref"} or increase plasma levels of natriuretic peptides through inhibition of neprilysin, such as sacubitril/valsartan,[13](#ehf212567-bib-0013){ref-type="ref"} have shown clinical benefits in the last decade.

In May 2016, a new version of the European Society of Cardiology (ESC) Guidelines for the management of acute and chronic HF was released.[14](#ehf212567-bib-0014){ref-type="ref"} The document included updated recommendations regarding the diagnosis, pharmacological and invasive treatment of these patients, such as introduction of sacubitril/valsartan as a class I therapy, or recommendations for the early initiation of key HF drugs.

To our knowledge, no major registries of HFrEF outpatients have been published after the publication of ESC 2016 Guidelines.[14](#ehf212567-bib-0014){ref-type="ref"} The purpose of the present study was thus to (i) describe the characteristics of a large population HFrEF patients recruited after ESC 2016 Guidelines[14](#ehf212567-bib-0014){ref-type="ref"} release, (ii) compare the pharmacological and invasive management of HFrEF patients by level of hospital complexity, and (iii) compare this management with those from previous registries.

2. Methods {#ehf212567-sec-0006}
==========

2.1. Study design and population {#ehf212567-sec-0007}
--------------------------------

The Linx registry is a multicentre, observational, cross‐sectional study from 14 Catalan hospitals (*Figure* [*1*](#ehf212567-fig-0001){ref-type="fig"}) aimed at assessing the impact of the new ESC 2016 Guidelines[14](#ehf212567-bib-0014){ref-type="ref"} in the management of HFrEF outpatients in the real‐world setting.

![Hospital geographical location. 1. Hospital Universitari de Bellvitge (L\'Hospitalet de Llobregat), 2. Hospital Clinic (Barcelona), 3. Hospital Universitari Germans Trias i Pujol (Badalona), 4. Hospital de la Santa Creu i Sant Pau (Barcelona), 5. Hospital Universitari Vall d\'Hebron (Barcelona), 6. Hospital Universitari Arnau de Vilanova (Lleida), 7. Hospital del Mar (Barcelona), 8. Corporació Sanitària Parc Taulí (Sabadell), 9. Hospital de Figueres (Figueres), 10. Hospital de Granollers (Granollers), 11. Hospital Moisès Broggi (Sant Joan Despí), 12. Hospital Sant Joan de Deu de Martorell (Martorell), 13. Hospital de Mataró (Mataró), 14. Hospital de Viladecans (Viladecans). 1--5 tertiary hospitals, 6--8 secondary hospitals, 9--14 primary hospitals.](EHF2-7-25-g001){#ehf212567-fig-0001}

For the Linx registry, patients were prospectively enrolled from the outpatient cardiology clinics of each participating hospital from 1 February to 30 April 2017. This included general cardiology clinics (mostly in primary hospitals) as well as specialized HF clinics (typically in tertiary hospitals). Inclusion criteria were a diagnosis of HF according ESC 2016 Guidelines[14](#ehf212567-bib-0014){ref-type="ref"} and reduced LVEF (defined by LVEF ≤40% in the most recent echocardiography during follow‐up). Exclusion criteria were age under 18 years old, use of left ventricular assist devices, or heart transplantation before study entry. All of these patients were included in the present analysis.

Patients included in the Linx registry were managed according to the local HFrEF management protocols; at the time of inclusion, there were no regulatory restrictions to prescription of angiotensin receptor neprilysin inhibitor (ARNI). For the present analysis, the outpatient clinic visit in which patients were included in the study will be considered the 'index\' visit.

2.2. Data collection {#ehf212567-sec-0008}
--------------------

Information on demographic characteristics, HF aetiology, key HF clinical variables (e.g. LVEF and New York Heart Association functional class), and relevant co‐morbidities was collected by local researchers using the local medical records. Information on vital signs and electrocardiographic parameters was obtained from the information generated in the most recent outpatient clinic visit before study entry. Data on blood sample tests \[including levels of N‐terminal pro‐B type natriuretic peptide (NT‐proBNP)\] and echocardiographic parameters were obtained from the most recent tests before study entry.

Data on pharmacological therapies \[including beta‐blockers, angiotensin‐converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARBs), mineralocorticoid receptor antagonists (MRAs), ARNIs, and ivabradine, among others\], their doses, and use of key HF devices \[cardiac resynchronization therapy (CRT) and implantable cardioverter defibrillator (ICD)\] were collected by local researchers at the end of the index visit.

2.3. Definition of hospital type {#ehf212567-sec-0009}
--------------------------------

In order to compare the clinical characteristics and pharmacological management between hospitals according to their level of complexity, we classified recruiting centres in three categories: primary, secondary, and tertiary. Hospitals providing neither interventional cardiology nor cardiac surgery were classified as primary centres (six), hospitals providing interventional cardiology but not cardiac surgery were classified as secondary centres (three), and hospitals providing both were classified as tertiary centres (five). This classification has been widely used in previously published HF registries.[15](#ehf212567-bib-0015){ref-type="ref"}

2.4. Statistical analyses {#ehf212567-sec-0010}
-------------------------

Descriptive statistics were used to summarize the characteristics of the study participants, including therapies and drug doses. Categorical variables are presented as number and percentage, continuous variables with normal distribution are presented using mean and standard deviation, and non‐normal continuous variables are presented using median and interquartile range.

In the comparative analyses by level of hospital complexity, these characteristics were compared using chi‐squared tests for categorical variables, and ANOVA and non‐parametric tests for continuous variables, as appropriate.

The proportion of patients in whom target doses of each key HF pharmacotherapy were achieved (according to ESC 2016 Guidelines[14](#ehf212567-bib-0014){ref-type="ref"}) was also calculated, overall and by hospital type. As a graphical, intuitive summary, these proportions were plotted using a radial graph or 'radar chart\'.[26](#ehf212567-bib-0026){ref-type="ref"} Although this graph has not been common in HF research, it allows accommodating in one single image multiple data (in the present analysis, multiple data on target dose use) in a more efficient way than traditional bar charts. It also allows calculating the area of the polygon, and the proportion over the total area, as summary measures. Specifically, we calculated the proportion over the total area for four polygons, as a percentage of the maximum theoretical target dose: overall (i.e. all hospitals), tertiary, secondary, and primary hospitals. More details on the calculations performed for the radial graph are presented in the Supporting Information, Data S1.

We also compared the overall proportions of users of each drug type and of HF devices in the Linx registry, with the results of the Spanish cohort of the ESC Heart Failure Long‐term Registry,[16](#ehf212567-bib-0016){ref-type="ref"} a similar multicentre registry including 1526 Spanish HFrEF patients, published before the release of the ESC 2016 Guidelines. Proportions were compared again using the chi‐squared statistic.

Finally, we plotted the present results together with the results from similar, previously published landmark European HFrEF registries conducted since 2003, as means to provide historical context to the present findings.[7](#ehf212567-bib-0007){ref-type="ref"}, [17](#ehf212567-bib-0017){ref-type="ref"}, [18](#ehf212567-bib-0018){ref-type="ref"}, [19](#ehf212567-bib-0019){ref-type="ref"}

All statistical analyses were centralized in one of the recruiting centres and were performed using Excel version 16 (Microsoft, Redmond, Washington, USA) and Stata software version 15.0 (StataCorp, College Station, Texas, USA). A two‐tailed *P* value \<0.05 was considered statistically significant.

3. Results {#ehf212567-sec-0011}
==========

3.1. Study participants {#ehf212567-sec-0012}
-----------------------

Between 1 February and 30 April 2017, 1056 HFrEF patients were prospectively enrolled in the registry; 604 patients (57.2%) were recruited from tertiary hospitals, 144 patients (13.6%) from secondary hospitals, and 308 patients (29.2%) from primary hospitals.

3.2. Demographic characteristics and clinical profile of the study participants {#ehf212567-sec-0013}
-------------------------------------------------------------------------------

*Table* [1](#ehf212567-tbl-0001){ref-type="table"} summarizes the characteristics of 1056 HFrEF patients included in the registry. Overall, mean age was 66.5 years, and 78.9% of patients were men. Ischaemic cardiomyopathy was the most frequent aetiology of HF (42.3%), followed by idiopathic dilated cardiomyopathy (32.7%). Median LVEF was 30%, and only 14.5% of patients were asymptomatic, while more than half (58.4%) had mild HF symptoms (New York Heart Association II). Median NT‐proBNP was 1861 pg/mL, and 66.5% of patients had a previous admission for HF. Left bundle branch block was present in 33.6% of patients. With regard to co‐morbidities, 40% of patients had atrial fibrillation, 34.7% had chronic kidney disease, and 23.7% had chronic obstructive pulmonary disease.

###### 

Demographics and clinical profile of patients

                                Overall (*N* = 1056)   Tertiary (*N* = 604)   Secondary (*N* = 144)   Primary (*N* = 308)     *P* value
  ----------------------------- ---------------------- ---------------------- ----------------------- ----------------------- -----------
  Demographics                                                                                                                
  Age (years)                   66.5 (12.3)            64.3 (12.3)            67.1 (12.1)             70.4 (11.5)             \<0.001
  Male sex                      815 (78.9)             481 (80.8)             98 (74.2)               236 (77.1)              0.162
  HF aetiology                                                                                                                \<0.001
  Ischaemic                     404 (42.3)             232 (46.0)             55 (38.2)               117 (38.1)              
  Valvular                      70 (7.3)               33 (6.6)               13 (9.0)                24 (7.8)                
  Hypertensive                  22 (2.3)               9 (1.8)                7 (4.9)                 6 (1.95)                
  Alcoholic                     29 (3.0)               18 (3.6)               4 (2.8)                 7 (2.3)                 
  Other toxics                  18 (1.9)               8 (1.6)                10 (5.1)                2 (0.6)                 
  Non‐compaction                26 (2.7)               20 (4.0)               3 (2.1)                 3 (1.0)                 
  Mixed                         41 (4.3)               27 (5.4)               2 (1.4)                 12 (3.9)                
  IDC                           312 (32.7)             140 (27.8)             44 (30.6)               128 (41.7)              
  Others                        33 (3.5)               17 (3.4)               8 (5.6)                 18 (2.6)                
  LVEF (%)                      30 (25, 35)            31 (25, 35)            30 (25, 35)             30 (25, 35)             0.552
  NYHA class                                                                                                                  \<0.001
  I                             153 (14.5)             65 (10.8)              32 (22.2)               56 (18.2)               
  II                            616 (58.4)             341 (56.6)             92 (63.9)               183 (59.6)              
  III                           265 (25.1)             183 (30.4)             19 (13.2)               63 (20.5)               
  IV                            20 (1.9)               14 (2.3)               1 (0.7)                 5 (1.6)                 
  Previous admission            701 (66.5)             396 (65.6)             115 (79.9)              190 (61.9)              0.001
  Vital signs                                                                                                                 
  SBP (mmHg)                    117.6 (18.6)           115.0 (18.2)           120.9 (17.6)            121.1 (19.0)            \<0.001
  DBP (mmHg)                    70.9 (11)              71.7 (10.0)            69.8 (11.3)             69.78 (12.5)            0.020
  HR (b.p.m.)                   68.9 (12.6)            67.7 (11.6)            70.5 (14.8)             70.4 (13.3)             0.002
  Cardiovascular risk factors                                                                                                 
  Current smoker                136 (12.9)             71 (11.8)              24 (16.7)               41 (13.4)               0.275
  Previous smoker               559 (53.7)             337 (56.5)             65 (45.8)               157 (51.8)              0.051
  Hypertension                  700 (66.4)             389 (64.4)             96 (66.7)               215 (70.0)              0.235
  Diabetes mellitus             419 (39.7)             231 (38.3)             60 (41.7)               128 (41.7)              0.528
  Dyslipemia                    648 (61.5)             371 (61.4)             83 (57.6)               194 (63.4)              0.503
  Co‐morbidities                                                                                                              
  OSAS                          132 (12.5)             80 (13.3)              19 (13.1)               33 (10.8)               0.551
  COPD                          250 (23.7)             126 (20.9)             40 (27.8)               84 (27.5)               0.041
  Stroke                        97 (9.2)               66 (10.9)              10 (6.9)                21 (6.9)                0.081
  Vasculopathy                  117 (11.1)             70 (11.6)              12 (8.3)                35 (11.4)               0.522
  CKD                           366 (34.7)             211 (34.9)             44 (30.8)               111 (36.3)              0.516
  AF                                                                                                                          \<0.001
  No                            632 (60.0)             379 (62.8)             83 (57.6)               170 (55.7)              
  Paroxistic                    91 (8.6)               43 (7.1)               22 (15.3)               26 (8.5)                
  Persist/perman.               144 (13.7)             68 (11.3)              31 (21.5)               45 (14.8)               
  Non‐defined                   186 (17.6)             114 (18.9)             8 (5.7)                 64 (21.0)               
  Biomarkers                                                                                                                  
  Haemoglobin (g/dL)            13.4 (1.9)             13.4 (1.8)             13.5 (2.3)              13.3 (1.9)              0.725
  Creatinine (mg/dL)            1.1 (0.9, 1.4)         1.1 (0.9, 1.5)         1.1 (0.9, 1.4)          1.1 (0.9, 1.4)          0.619
  BNP (pg/mL)                   296 (200, 891)         306 (204, 956)         219 (136.9, 335)        1782 (484, 3080)        0.012
  NT‐proBNP (pg/mL)             1861 (694, 4307)       1418 (635, 4108)       2957 (1182, 4794)       2390 (1022.5, 4424.5)   0.006
  Ferritin (ng/mL)              154.5 (72, 284)        143.5 (65, 280)        145 (72, 328)           180 (94, 294)           0.268
  TSI (%)                       20.3 (15, 28)          21 (15, 29)            18.7 (14.5, 26)         20 (15.6, 28)           0.260
  ECG                                                                                                                         
  Rhythm                                                                                                                      \<0.001
  Sinus                         715 (68.4)             444 (74.0)             93 (64.6)               178 (58.9)              
  AF                            227 (21.7)             118 (19.7)             31 (21.5)               78 (25.8)               
  Paced                         99 (9.5)               34 (5.7)               19 (13.2)               46 (15.2)               
  Atrial flutter                5 (0.5)                4 (0.7)                1 (0.7)                 0 (0)                   
  LBBB                          353 (33.6)             194 (32.1)             48 (33.3)               111 (36.5)              0.425
  Echocardiography                                                                                                            
  LVEDD (mm)                    63.1 (8.8)             63.8 (9)               62.8 (8.0)              61.8 (8.6)              0.005
  E/A                           1 (0.7, 1.8)           1.1 (0.7, 2.0)         0.9 (0.7, 1.4)          0.8 (0.6, 1.5)          \<0.001
  LA (mm)                       47.3 (8.5)             47.1 (8.8)             47.8 (8.6)              47.4 (7.7)              0.671
  MR mod/sev                    375 (35.9)             223 (37.2)             37 (25.9)               115 (38.0)              0.026
  PH                            267 (25.9)             173 (29.1)             27 (19.7)               67 (22.3)               0.019

AF, atrial fibrillation; BNP, brain natriuretic peptide; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; ECG, electrocardiogram; HF, heart failure; HR, heart rate; IDC, idiopathic dilated cardiomyopathy; LA, left atrium; LBBB, left bundle branch block; LVEDD, left ventricular end‐diastolic diameter; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; NT‐proBNP, N‐terminal pro‐B type natriuretic peptide; NYHA, New York Heart Association; OSAS, obstructive sleep apnoea syndrome; PH, pulmonary hypertension; SBP, systolic blood pressure; TSI, transferrin saturation index.

In hospitals with higher level of complexity, patients were younger, and ischaemic cardiomyopathy was more frequent than in less complex centres. There were no differences between hospital types in terms of sex distribution or median LVEF. The burden of co‐morbidities was also similar across groups, except for atrial fibrillation and for chronic obstructive pulmonary disease, which were more frequent in hospitals with lower complexity. Median NT‐proBNP levels were higher in secondary hospitals, whereas the lowest levels were those of tertiary hospitals. Mean systolic blood pressure and mean heart rate were slightly lower in patients from tertiary hospitals compared with the other centres.

3.3. Pharmacological management and devices {#ehf212567-sec-0014}
-------------------------------------------

*Figure* [*2*](#ehf212567-fig-0002){ref-type="fig"} shows the pharmacological and invasive management of our study population. Overall, beta‐blockers were used in 91.8% of patients, ACE‐I in 48.1%, ARB in 16.9%, sacubitril/valsartan in 23.9%, MRA in 72.7%, and ivabradine in 21.4% patients. CRT and ICD were used in 15.6% and 26.3% of patients, respectively.

![Drugs and devices. ACE‐I, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; CRT, cardiac resynchronization therapy; ICD, implantable cardioverter defibrillator; MRA, mineralocorticoid receptor antagonist; PCI, percutaneous coronary intervention.](EHF2-7-25-g002){#ehf212567-fig-0002}

In the comparative analyses by level of complexity, beta‐blockers were more frequently prescribed in tertiary hospitals, while renin--angiotensin inhibitors globally were more frequently prescribed in secondary centres. Primary hospitals had the highest proportion of patients under treatment with sacubitril/valsartan (37.2%), whereas there was a trend towards higher prescription of MRAs in hospitals with higher level of complexity (75.7% in secondary hospitals and 78.1% in tertiary hospitals).

There was a trend towards greater use of devices (ICD and CRT) in hospitals with higher complexity; and patients from tertiary and secondary hospitals had undergone percutaneous coronary revascularization more frequently.

*Table* [2](#ehf212567-tbl-0002){ref-type="table"} displays the combinations of drug prescription among patients. Overall, 62.7% of patients were under treatment with triple therapy (beta‐blockers + renin--angiotensin inhibitors + MRA). In line with the results showed in the previous paragraphs, there was also a trend towards higher proportion of patients under triple therapy in hospitals with higher level of complexity.

###### 

Combinations of drug prescription

                                    Overall (*N* = 1056)   Tertiary (*N* = 604)   Secondary (*N* = 144)   Primary (*N* = 308)   *P* value
  --------------------------------- ---------------------- ---------------------- ----------------------- --------------------- -----------
  BB (monotherapy)                  60 (5.7%)              26 (4.3%)              2 (1.4%)                32 (10.5%)            \<0.001
  MRA (monotherapy)                 6 (0.6%)               5 (0.8%)               0 (0%)                  1 (0.3%)              0.40
  iRA (monotherapy)                 24 (2.3%)              5 (0.8%)               3 (2.1%)                16 (5.3%)             \<0.001
  ACE‐I                             10 (1%)                3 (0.5%)               2 (1.4%)                5 (1.6%)              0.21
  ARB                               3 (0.3%)               1 (0.2%)               0 (0%)                  2 (0.7%)              0.33
  ARNI                              9 (0.9%)               1 (0.2%)               1 (0.7%)                7 (2.3%)              0.004
  BB + iRA (bitherapy)              190 (18.2%)            94 (15.7%)             29 (20.1%)              67 (22.1%)            0.048
  BB + ACE‐I                        109 (10.5%)            58 (9.8%)              18 (12.5%)              33 (10.9%)            0.612
  BB + ARB                          34 (3.2%)              16 (2.7%)              9 (6.3%)                9 (3%)                0.087
  BB + ARNI                         34 (3.2%)              9 (1.5%)               2 (1.4%)                23 (7.6%)             \<0.001
  BB + MRA (bitherapy)              50 (4.8%)              28 (4.7%)              9 (6.3%)                13 (4.3%)             0.66
  iRA + MRA (bitherapy)             46 (4.4%)              20 (3.3%)              5 (3.5%)                21 (7%)               0.035
  ACE‐I + MRA                       25 (2.4%)              15 (2.5%)              4 (2.8%)                6 (2%)                0.841
  ARB + MRA                         8 (0.8%)               2 (0.3%)               1 (0.7%)                5 (1.7%)              0.097
  ARNI + MRA                        11 (1.1%)              2 (0.4%)               0 (0%)                  9 (3%)                \<0.001
  BB + iRA + MRA (triple therapy)   653 (62.7%)            415 (69.2%)            95 (66%)                143 (48%)             \<0.001
  BB + ACE‐I + MRA                  328 (31.8%)            226 (38.3%)            51 (35.4%)              51 (17.1%)            \<0.001
  BB + ARB + MRA                    119 (11.4%)            85 (14.1%)             13 (9%)                 21 (7%)               0.004
  BB + ARNI + MRA                   179 (17.2%)            89 (14.8%)             31 (21.5%)              59 (20.1%)            0.047

ACE‐I, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; BB, beta‐blockers; iRA, renin--angiotensin inhibitors; MRA, mineralocorticoid receptor antagonist.

3.4. Specific drugs and drug doses {#ehf212567-sec-0015}
----------------------------------

*Table* [3](#ehf212567-tbl-0003){ref-type="table"} describes the use of specific drugs within each family, and their mean doses, overall and by level of complexity. Overall, the most frequently prescribed drugs within each family were enalapril among ACEI (73.4%, mean dose 12 mg/day), bisoprolol among beta‐blockers (54.9%, mean dose 5.6 mg/day), losartan among ARBs (40.6%, mean dose 78 mg/day), and eplerenone among MRAs (65.8%, mean dose 29.7 mg/day). Mean dose of sacubitril/valsartan was 144.8 mg/day, and mean dose of ivabradine was 11 mg/day.

###### 

Drug prescription and doses (mg/day)

                         Overall        Tertiary       Secondary      Primary        *P* value
  ---------------------- -------------- -------------- -------------- -------------- -----------
  ACE‐I                                                                              
  Enalapril (*n*, %)     373 (73.4%)    262 (79.6%)    51 (65.4%)     60 (59.4%)     \<0.001
  Mean dose (SD)         12 (9)         12.2 (8.4)     14.7 (11.4)    8.7 (7.8)      ---
  Ramipril (*n*, %)      118 (23.2%)    58 (17.6%)     23 (29.5%)     37 (36.6%)     ---
  Mean dose (SD)         4.5 (2.8)      4.6 (2.8)      5.3 (3.1)      4.0 (2.6)      ---
  Lisinopril (*n*, %)    9 (1.8%)       6 (1.8%)       1 (1.3%)       2 (2%)         ---
  Mean dose (SD)         13.1 (15.4)    11.3 (14.3)    5 (0)          22.5 (24.7)    ---
  Captopril (*n*, %)     1 (0.2%)       0 (0%)         0 (0%)         1 (1%)         ---
  Mean dose (SD)         25 (0)         ---            ---            25 (0)         ---
  Perindopril (*n*, %)   5 (1%)         1 (0.3%)       3 (3.9%)       1 (1.0%)       ---
  Mean dose (SD)         3.6 (2.6)      8 (0)          2 (0)          4 (0)          ---
  Others (*n*, %)        2 (0.4%)       2 (0.6%)       0 (0%)         0 (0%)         ---
  ARB                                                                                
  Valsartan (%)          63 (37.1%)     39 (35.8%)     16 (66.7%)     8 (21.6%)      0.002
  Mean dose (SD)         120.7 (85.1)   115.6 (76.3)   110.9 (83.6)   320 (0)        ---
  Losartan (%)           69 (40.6%)     44 (40.4%)     5 (20.8%)      20 (54%)       ---
  Mean dose (SD)         78 (46.6)      80.4 (44.0)    ---            68.8 (57.9)    ---
  Candesartan (%)        26 (15.3%)     20 (18.4%)     2 (8.3%)       4 (10.8%)      ---
  Mean dose (SD)         21.8 (16.9)    22.2 (17.8)    ---            18 (2.8)       ---
  Olmesartan (%)         6 (3.5%)       1 (0.9%)       1 (4.2%)       4 (10.8%)      ---
  Mean dose (SD)         40 (0)         ---            ---            40 (0)         ---
  Irbesartan (%)         5 (2.9%)       5 (4.6%)       0 (0%)         0 (0%)         ---
  Mean dose (SD)         150 (0)        150 (0)        ---            ---            ---
  Telmisartan (%)        1 (0.6%)       0 (0%)         0 (0%)         1 (2.7%)       ---
  Mean dose (SD)         80 (0)         ---            ---            80 (0)         ---
  Beta‐blockers                                                                      
  Bisoprolol (%)         519 (54.9%)    268 (48.6%)    66 (48.3%)     185 (71.4%)    \<0.001
  Mean dose (SD)         5.6 (3.3)      6.4 (3.4)      6.5 (3.8)      4.1 (2.4)      ---
  Carvedilol (%)         390 (41.2%)    258 (46.8%)    69 (50.7%)     63 (24.3%)     ---
  Mean dose (SD)         26.6 (18.4)    26.2 (17.4)    33.2 (21.3)    20.8 (16.6)    ---
  Metoprolol (%)         1 (0.1%)       1 (0.2%)       0 (0%)         0 (0%)         ---
  Mean dose (SD)         100 (0)        100 (0)        ---            ---            ---
  Nevibolol (%)          35 (3.7%)      24 (4.4%)      0 (0%)         11 (4.3%)      ---
  Mean dose (SD)         4.5 (2.5)      4.7 (2.9)      ---            4 (1.5)        ---
  Others (%)             1 (0.1%)       0 (0%)         1 (0.7%)       0 (0%)         
  MRA                                                                                
  Spironolactone (%)     262 (34.2%)    161 (34.2%)    31 (28.4%)     70 (37.6%)     0.275
  Mean dose (SD)         28.2 (18.1)    27.6 (18.7)    27.8 (16.7)    29.6 (17.3)    ---
  Eplerenone (%)         504 (65.8%)    310 (65.8%)    78 (71.6%)     116 (62.4%)    ---
  Mean dose (SD)         29.7 (12.5)    31.1 (13.6)    29.9 (11.7)    26.1 (8.7)     ---
  Ivabradine                                                                         
  Mean dose (SD)         11 (3.3)       10.9 (3.6)     11.2 (2.9)     11.1 (2.9)     ---
  Sacubitril/valsartan                                                               
  Mean dose (SD)         144.8 (94)     160.5 (101)    144.1 (94.4)   130.4 (85.4)   ---

ACE‐I, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, mineralocorticoid receptor antagonist; *n*, number; SD, standard deviation.

The observations with regard to the most frequently used drug subtypes were also true across all levels of complexity, except for valsartan and carvedilol, which were the most frequently used ARB and beta‐blocker, respectively, in secondary hospitals.

3.5. Target doses of key heart failure drugs {#ehf212567-sec-0016}
--------------------------------------------

The proportion of patients in whom target doses of each key HF pharmacotherapy were achieved (according to ESC 2016 Guidelines[14](#ehf212567-bib-0014){ref-type="ref"}) is displayed in *Figure* [*3*](#ehf212567-fig-0003){ref-type="fig"}, overall and by level of hospital complexity. Overall, target doses of ACEI and beta‐blockers were achieved in approximately 25% of patients, MRA in 20%, while for ARB and ARNI, target doses were achieved only in less than 10% of patients.

![Target dose. ACE‐I, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; MRA, mineralocorticoid receptor antagonist.](EHF2-7-25-g003){#ehf212567-fig-0003}

Although tertiary hospitals achieved target doses of ARBs, MRAs, ivabradine, and ARNI more frequently than the other centres, for beta‐blockers and ACEI, target doses were achieved more frequently in secondary hospitals. On the other hand, the lowest adherence to guideline‐recommended target doses was observed in primary centres (graph area 1.7%).

3.6. Comparison with prior registries {#ehf212567-sec-0017}
-------------------------------------

*Table* [4](#ehf212567-tbl-0004){ref-type="table"} compares the observations from our registry to a similar Spanish registry[16](#ehf212567-bib-0016){ref-type="ref"} published before the release of the ESC 2016 Guidelines. In Linx, the use of ACEI, ARBs, and any renin--angiotensin inhibitors (ACE‐I, ARB, or ARNI) was slightly lower than in the 2015 registry (before commercialization of sacubitril/valsartan). There was also a statistically significant decrease in the use of digoxin after the ESC 2016 Guidelines.[14](#ehf212567-bib-0014){ref-type="ref"} No other statistically significant differences were observed between the two studies.

###### 

Drugs prescription comparison with previous registries from Spain

                           ESC Heart Failure Long‐term Registry^17^ (LVEF ≤ 40%) (*N* = 1526)   Linx registry (*N* = 1056)   *P* value
  ------------------------ -------------------------------------------------------------------- ---------------------------- -----------
  ACE‐I (%)                64.6                                                                 48.1                         \<0.001
  ARB (%)                  29.1                                                                 16.9                         \<0.001
  ARNI (%)                 ---                                                                  23.9                         ---
  ACE‐I + ARB + ARNI (%)   92.6                                                                 86.9                         \<0.001
  Beta‐blockers (%)        93.3                                                                 91.8                         0.15
  MRA (%)                  74.5                                                                 72.7                         0.31
  Diuretics (%)            83.3                                                                 83.5                         0.89
  Digoxin (%)              22                                                                   14.1                         \<0.001
  Ivabradine (%)           19.7                                                                 21.4                         0.29
  Nitrates (%)             16.8                                                                 19.7                         0.06

ACE‐I, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; ESC, European Society of Cardiology; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist.

3.7. Temporal trends {#ehf212567-sec-0018}
--------------------

The temporal trends in pharmacological and device management of outpatients with HFrEF in Europe from 2003 (SWEDE‐HEART registry[17](#ehf212567-bib-0017){ref-type="ref"}) to the present (Linx) are presented in *Figure* [*4*](#ehf212567-fig-0004){ref-type="fig"}, which summarizes the observations from key, comparable, European HFrEF observational studies. The proportion of patients treated with beta‐blockers and ACEI/ARBs remained stable over time (around 90%), until commercialization of sacubitril/valsartan, which, as evidenced in our registry, has been associated with a marked decrease in the use of ACEI. MRA use has steadily increased in the last decade, so has the use of ICD and CRT.

![The temporal trends in pharmacological and device management of outpatients with heart failure with reduced ejection fraction in Europe. ACE‐I, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; BB, beta‐blockers; CRT, cardiac resynchronization therapy; ESC‐HF‐LT, European Society of Cardiology Heart Failure Long‐Term Registry; ICD, implantable cardioverter defibrillator; MRA, mineralocorticoid receptor antagonist.](EHF2-7-25-g004){#ehf212567-fig-0004}

4. Discussion {#ehf212567-sec-0019}
=============

The Linx registry shows that after the release of the ESC 2016 Guidelines,[14](#ehf212567-bib-0014){ref-type="ref"} use of beta‐blockers remained very high in HFrEF patients, while there was a marked decrease in the use of ACE‐I/ARBs in monotherapy, which was likely the consequence of a marked increase in the use of sacubitril/valsartan. When considering hospital complexity, we observed that beta‐blockers, MRAs, and devices were more frequently used in tertiary hospitals (where the population was younger and median NT‐proBNP levels were lower), while sacubitril/valsartan was more frequently used in primary hospitals. In all centres, achievement of the target drug doses recommended by the ESC 2016 Guidelines[14](#ehf212567-bib-0014){ref-type="ref"} was low.

Our first main finding is the very high uptake of sacubitril/valsartan, only a few months after ESC 2016 Guidelines[14](#ehf212567-bib-0014){ref-type="ref"} recommendation to replace ACE‐I for ARNI in ambulatory patients with HFrEF who remain symptomatic despite optimal medical treatment. The proportion reached 24% in our population and was even higher in primary hospitals. Given the recent publication of safety data showing that early initiation of ARNI might be feasible and tolerable,[20](#ehf212567-bib-0020){ref-type="ref"} this proportion is likely to keep growing in the coming years. Further studies will provide valuable insights on this question.

Our results also suggest a trend towards a better adherence to ESC HF Guideline recommendations in hospitals with higher level of complexity. Whether these disparities are the consequence of differences in the clinical profiles of the patient populations from each type of hospital, or of other factors, cannot be concluded from the available data. Nevertheless, some differences in demographic and clinical characteristics were observed across centres---e.g. patients from tertiary hospitals were younger, which might explain a higher tolerance to beta‐blockers, and therefore the more frequent use of this drug group; and patients from secondary and primary hospitals were older and had more co‐morbidities, such as chronic obstructive pulmonary disease. Despite the fact that there are no previous studies comparing management of HFrEF outpatients by hospital type, some studies[21](#ehf212567-bib-0021){ref-type="ref"}, [22](#ehf212567-bib-0022){ref-type="ref"}, [23](#ehf212567-bib-0023){ref-type="ref"} also suggest better outcomes in patients admitted for HF in higher volume hospitals, although in a recently published registry (GWTG‐HF)[24](#ehf212567-bib-0024){ref-type="ref"} this trend was not confirmed.

We also observed a low proportion of patients meeting the recommended target doses of most class I HFrEF therapies. A potential explanation to this finding, as discussed in the ESC 2016 Guidelines,[14](#ehf212567-bib-0014){ref-type="ref"} is the fact that some of the clinical trials in which those target doses were defined were conducted before the availability of modern therapies such as eplerenone or sacubitril/valsartan, among others. Also, the patient populations included in those studies tended to be young and to have few co‐morbidities; conversely, in our real‐life patient population, the prevalence of key co‐morbidities such as chronic kidney disease or chronic obstructive pulmonary disease was high. In addition, it is important to note that information on drug use, drug doses, and device use was recorded at study entry (i.e. not necessarily at end of titration). This means that many patients might have been treated with additional therapies, might have had some drug doses titrated, or might have been treated with specific HF devices later in time (i.e. during follow‐up in the cardiology clinic), as part of standard pharmacological titration and progressive therapeutic optimization. Therefore, the present observations regarding target doses and device use should be interpreted cautiously.

Importantly, our findings regarding the very low proportion of patients meeting target doses are consistent with those from prior registries.[7](#ehf212567-bib-0007){ref-type="ref"}, [17](#ehf212567-bib-0017){ref-type="ref"}, [18](#ehf212567-bib-0018){ref-type="ref"}, [19](#ehf212567-bib-0019){ref-type="ref"}, [25](#ehf212567-bib-0025){ref-type="ref"} Indeed, achieving target doses of pharmacological therapies proven to reduce mortality remains as a major challenge for the management of patients with chronic HFrEF as recently described in CHAMP‐HF registry.[25](#ehf212567-bib-0025){ref-type="ref"} Compared with clinical practice in the USA, we found no differences in achieving target doses of ACE‐I/ARB (20.6% vs. 17.5%) or beta‐blockers (25.4% vs. 27.6%), but we found fewer patients in target doses regarding ARNI (8.1% vs. 14%) and MRA (19.7% vs. 76.6%). The greater proportion of target doses of MRA might be partly explained by a much lower proportion of patients prescribed with MRA (72.7% vs. 33.1%) that might select a group of patients with better renal function.

4.1. Study strengths {#ehf212567-sec-0020}
--------------------

To our knowledge, this is the first registry to evaluate the real‐world management of HFrEF in the outpatients setting in Europe since the publication of the ESC 2016 HF Guidelines. Moreover, because Linx is a multicentre, large registry, this maximized statistical power and the generalizability of the conclusions. In addition, because not only tertiary but also secondary and primary centres were included, we were able to compare hospitals by level of complexity, and this increased generalizability of our overall findings even further. Although secondary and primary centres are usually underrepresented in clinical trials and observational studies, they actually manage a large number of patients in routine clinical practice. Finally, the detailed information on drug dosage captured in Linx allowed evaluating adherence to guideline recommendations.

4.2. Study limitations {#ehf212567-sec-0021}
----------------------

One of the major limitations of the registry comes from the cross‐sectional design, which limits causal inference based on the observed differences. Another limitation is the absence of information in the registry describing the reason for not prescribing or up‐titrating medication or devices. It is highly likely that formal contraindications as well as limited tolerance to specific drugs would explain most of these scenarios. Finally, although participating hospitals are spread around Catalonia, most patients were recruited from the metropolitan area of Barcelona, so patients from rural areas might have been underrepresented.

5. Conclusions {#ehf212567-sec-0022}
==============

The Linx registry shows an appropriate adherence to pharmacological recommendations from ESC 2016 HF Guidelines despite that target doses of class I HF drugs were low in our population. These findings are consistent with the observations from prior observational, real‐life studies. On the other hand, almost one‐quarter of chronic HFrEF patients were under treatment with sacubitril/valsartan a few months after ESC 2016 HF Guidelines recommendation, prompting the reduction of ACE‐I/ARB use in this patient population. Use of sacubitril/valsartan was even greater in primary hospitals. Finally, use of beta‐blockers, MRA, and ivabradine remained similar to the prescription rates observed in previous Spanish HFrEF registries and was particularly high in tertiary centres.
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